Taysha Gene Therapies, Inc.
NASDAQ:TSHABiotechnology
Healthcare
$3.77 +1.53%
+$0.10 today
- Market cap
- $1.22B
- Beta
- 1.18
- P/E (TTM)
- -17.7
- EPS (TTM)
- -$0.35
52W Low $2.25High $7.30
Volume 2.17M
Average 2.73M
Income Statement
Follow revenue through to earnings.
Revenue
$9.77M
FY 2025 · Annual
+17.3% YoYOperating Income
-$110.50M
FY 2025 · Annual
Net Income
-$109.00M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 2.5M | 15.45M | 8.33M | 9.77M |
| Cost of Revenue | 0 | 2.49M | 0 | 0 | 0 |
| Gross Profit | 0 | 15K | 15.45M | 8.33M | 9.77M |
| Gross Margin | — | 0.6% | 100.0% | 100.0% | 100.0% |
| Research & Development | 131.94M | 91.17M | 56.78M | 66M | 86.4M |
| Selling, General & Admin | 41.32M | 34.87M | 30.05M | 28.95M | 33.87M |
| Operating Expenses | 173.27M | 126.04M | 87.89M | 99.79M | 120.27M |
| Depreciation & Amortization | 492K | 2.49M | 1.37M | 1.25M | 1.15M |
| EBITDA | (172.6M) | (159.73M) | (105.2M) | (87.95M) | (107.79M) |
| EBITDA Margin | — | -6384.1% | -680.8% | -1055.5% | -1102.9% |
| Operating Income | (173.27M) | (126.03M) | (72.44M) | (91.46M) | (110.5M) |
| Operating Margin | — | -5037.1% | -468.8% | -1097.6% | -1130.6% |
| Interest Income | 172K | 249K | 3.57M | 6.94M | 9.22M |
| Interest Expense | 1.43M | 3.8M | 5M | 102K | 63K |
| Other Income / Expenses | (1.26M) | (39.99M) | (39.13M) | 2.16M | 1.5M |
| Income Before Tax | (174.52M) | (166.01M) | (111.57M) | (89.3M) | (109M) |
| Pre-Tax Margin | — | -6635.3% | -722.1% | -1071.6% | -1115.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (174.52M) | (166.01M) | (111.57M) | (89.3M) | (109M) |
| Net Margin | — | -6635.3% | -722.1% | -1071.6% | -1115.3% |
| EPS (Basic) | (4.64) | (3.78) | (0.96) | (0.36) | (0.34) |
| EPS (Diluted) | (4.64) | (3.78) | (0.96) | (0.36) | (0.34) |
| 37.65M | 43.95M | 116.12M | 250.13M | 319.71M | |
| 37.65M | 43.95M | 116.12M | 250.13M | 319.71M |
TSHA Earnings Waterfall · TTM
NASDAQ:TSHA · Revenue to Net Income
Key Ratios
EPS$-0.42
Gross Margin23.6%
Net Margin-126.9%
P/E Ratio-12.1
P/S Ratio80.1
Analysis
$5.5M of revenue converted into -$149.6M of net income for the selected period. Gross margin is 23.6% and net margin is -126.9%, showing how much revenue survives after costs and taxes. EPS is $-0.42, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 13, 2026 | |
| 10-Q | Quarterly report | Aug 11, 2026 |
How much revenue does TSHA generate?
Taysha Gene Therapies, Inc. (TSHA) reported $9.77M of revenue in fiscal 2025.
Is TSHA profitable?
Taysha Gene Therapies, Inc. (TSHA) reported -$109.00M of net income, with a net margin of -1115.3%.
Continue the stock analysis
Jump to another research area for this company.